Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability and PK of Single Increasing Doses of Olcegepant in Healthy Volunteers
NCT02194335Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Oct 2000
- Primary completion
- Dec 2000
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, double-blind trial in migraine comparing BIBN 4096 BS with Placebo (2 arms). Primary endpoints: Number of patients with adverse events up to 24 days, Number of patients with abnormal changes in laboratory parameters up to 8 days and 2 more. Started Oct 2000; status: completed.
02
Drugs
olcegepant
03
Conditions
migraine
Beyond the preview
Go deeper on NCT02194335.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02194335.